236 Chapter 11 Table 1. Characteristics of included Reference Year Country Study Design Patient Inclusion Period Reasons for Patient Exclusion No. of Subjects No. of Genes Investigated Aim of the Study Start End Astrosini et al. 20 2008 Germany CH - - - 63 1 To investigate if REG1A is upregulated in CRC patients with unfavorable clinical outcome. Atreya et al. 43 2016 USA MCH 01/2013 09/2015 - 120 1 To investigate if BRAF V600E mutation is associated with sites and radiographic appearance of metastatic disease in patients matched by primary tumor location. Bruzzi et al. 21 2019 France CH 12/2005 11/2009 - 1650 2 To assess recurrence patterns according to microsatellite instability, RAS and BRAFV600E status in stage III. Cheng et al. 22 2018 Taiwan CH 2000 2013 History of other malignancies, inflammatory bowel disease or death within 30 days after surgery. 1969 1 To evaluate clinicopathological features, metastatic patterns, and prognostic value of CRC with the BRAFV600E mutation. Christensen et al. 44 2018 Denmark CH 01/2005 08/2008 Presence of other active tumors and no tissue sample or medical charts available. 448 3 To investigate associations between mutations and pattern of metastases. He et al. 23 2020 China CH 12/2015 02/2020 Non-metastatic synchronous CRC; neo-adjuvant therapy; location cecum, appendix or ileocecal junction; neuroendocrine components. 194 3 To investigate the connection between mutant KRAS, NRAS, and BRAF and clinicopathological characteristics in therapy-naïve synchronous mCRC in Chinese populations.
RkJQdWJsaXNoZXIy MTk4NDMw